Intraarticular sodium hyaluronate (Hyalgan®) in the treatment of patients with osteoarthritis of the knee: A randomized clinical trial

Journal of Rheumatology

Volumn 25, Issue 11, 1998, Pages 2203-2212

  Altman, Roy D ^a,b,c,f   Moskowitz, Roland ^d,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f NONE   (United States)

Author keywords

Hyaluronic acid; Intraarticular therapy; Osteoarthritis; Pain; Therapy; Viscosupplementation

Indexed keywords

HYALURONIC ACID; NAPROXEN; PARACETAMOL;

ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC APPROACH ROUTE; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAARTICULAR DRUG ADMINISTRATION; KNEE ARTHRITIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WALKING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; KNEE JOINT; MALE; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 0031731884     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kelsey JL. Epidemiology of musculoskeletal disorders. New York: Oxford University Press; 1982:78-86.
2. Scott JE. Hyaluronan, multum in parvo. Eur J Rheumatol Inflammation 1995;15:3-8.
3. Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis and disease. FASEB J 1993;7:1233-41.
4. Balazs EA. The physical properties of synovial fluid and the special role of hyaluronic acid. In: Helfet J. Disorders of the knee. 2nd edition. Philadelphia: Lippincott;1974:63-75.
5. Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int 1987;7:113-22.
6. 2 production in human osteoarthritis synovial cells. Agents Actions 1992;37:155-6.
7. 14C) arachidonic acid release from labelled human synovial fibroblasts. Japan J Pharmacol 1992;60:79-84.
8. Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of the synovial fluid. Clin Exp Rheumatol 1994;12:75-82.
9. Presti D, Scott JE. Hyaluronan mediated protective effect against cell damage caused by enzymatically produced hydroxyl (OH) radicals is dependent on hyaluronan molecular mass. Cell Biochem Function 1994;12:281-8.
10. Abatangelo G, Botti P, Del Bue M, et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. I. Biochemical results. Clin Orthop Rel Res 1989;241:278-85.
11. Schiavinato A, Lini E, Guidolin D, et al. Intraarticular sodium hyaluronate injections in the Pond-Nuki experimental model of osteoarthritis in dogs. II. Morphological findings. Clin Orthop Rel Res 1989;241:286-99.
12. Gotoh S, Miyazaki K, Onaya J, Sakamoto T, Tokuyasu K, Namiki O. Experimental knee pain model in rats and analgesic effect of sodium hyaluronate.(SPH) Folia Pharmacologica Japonica 1988;92:17-27.
13. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
14. Kellgren J, Lawrence J. Atlas of standard radiographs: The epidemiology of chronic rheumatism. Vol. 2. Oxford: Blackwell Scientific;1963.
15. Bellamy N, editor. Musculoskeletal clinical metrology. Dordrecht: Kluwer Academic;1993:205-6.
16. Altman R, Brandt K, Hochberg M, et al. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cart 1996;4:217-43.
17. Bellamy N, editor. WOMAC osteoarthritis index: a users guide. London, Ontario: Victoria Hospital;1995.
18. Dougados M, Nguyen M, Listrat V, Amor B. High molecular weight sodium hyaluronate (Hyalectin) in osteoarthritis of the knee. A 1-year placebo controlled trial. Osteoarthritis Cart 1993;1:97-103.
19. Dixon ASJ, Jacoby RK, Berry H, Hamilton EBD. Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee. Curr Med Res Opin 1988;11:205-13.
20. Leardini G, Mattara L, Franceschini M, Perbellini A. Intraarticular treatment of knee osteoarthritis. A comparative study between hyaluronic acid and 6-methyl prednisolone acetate. Clin Exp Rheumatol 1991;9:375-81.
21. Pietrogrande V, Melanotte PL, D'Angolo B, Pierfederici P, Perbellini A. Hyaluronic acid versus methylprednisolone intraarticularly injected for treatment of osteoarthritis of the knee. Curr Ther Res 1991;50:691-701.
22. Henderson EB, Smith EC, Pegley F, Blake DR. Intraarticular injection of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single-centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis 1994;53:529-34.
23. Carrabba M, Paresce E, Angelini M, Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. Eur J Rheumatol Inflammation 1995;15:25-32.
24. Donnelly S, Huskisson EC. Intraarticular hyaluronic acid in the treatment of osteoarthritis of the knee. Rheumatology in Europe 1995;24 Suppl 3:333.
25. Jones AC, Pattrick M, Doherty S, Doherty M. Intra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Osteoarthritis Cart 1995;3:269-73.
26. Listrat V, Ayral X, Patarnello F, et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cart 1997;5:153-60.
27. Puhl W, Bernau A, Greiling H, et al. Intraarticular sodium hyaluronate in osteoarthritis of the knee: a multicentre double-blind study. Osteoarthritis Cart 1993;1:233-41.
28. Dahlberg L, Lohmander LS, Ryd L. Intraarticular injections of hyaluronan in patients with cartilage abnormalities and knee pain: a one-year double blind placebo-controlled study. Arthritis Rheum 1994;37:521-8.
29. Lohmander LS, Dalen N, Englund G, Hyaluronan MultiCentre Trial Group. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled, multicentre trial. Ann Rheum Dis 1996;55:424-31.
30. Adams ME, Atkinson MH, Lussier AJ, et al. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicentre trial comparing hylan G-F 20 alone, hylan G-F 20 with NSAID, and NSAID alone. Osteoarthritis Cart 1995;3:213-25.
31. Hochberg MC, Altman RD, Brandt KD, et al. American College of Rheumatology guidelines for the medical management of Osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6.
32. Bellamy N, Carette S, Ford PM, et al. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials - results of a consensus development (Delphi) exercise. J Rheumatol 1992;19:451-57.